Medical directoryActive ingredient
Foundayo
A brand name associated with orforglipron, a GLP-1 receptor agonist mentioned in the ATTAIN-1 trial with 12.4% weight loss at 72 weeks.
Institutional endorsement by Clínica Evolution
Medical guides
Orforglipron (Foundayo), approved by the FDA: the first GLP-1 pill that can be taken without food or water restrictions
ReadOrforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain
ReadRetatrutide: what its phase 3 trial found, and why you can't get hold of it
ReadCagriSema: what it is, what the REDEFINE trials found and why it disappointed
Read
Keep reading
This entry is for information. Your case requires an individual medical assessment.